// App-Quantinova.ai

CT035 : TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia

Researchers

Presenter

  • Jayakumar Vadakekolathu

Principal Investigators

  • Catherine Lai

  • Stephen Reeder

  • Sarah E. Church

  • Tressa Hood

  • John Muth

  • Heidi Altmann

  • Marilena Ciciarello

  • Antonio Curti

  • Peter J. Valk

  • Bob Lwenberg

  • Martin Bornhuser

  • John F. DiPersio

  • Jan K. Davidson-Moncada

  • Sergio Rutella

Medical Centers

  • John van Geest Cancer Research Centre,Nottingham Trent University,Nottingham,United Kingdom

  • Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC

  • NanoString Technologies, Inc., Seattle, WA

  • MacroGenics, Inc., Rockville, MD

  • University Hospital Carl Gustav Carus, Technische Universitat, Dresden, Germany.

  • Institute of Hematology 'L. and A. Seràgnoli', Department of Oncology and Hematology, University-Hospital S.Orsola-Malpighi,Bologna,Italy

  • Department of Immunology, Erasmus Medical Center, Rotterdam, Netherlands

  • Division of Oncology, Department of Internal Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO

Locations

  • United Kingdom

  • United States

  • Germany

  • Italy

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 2AP

Drug/Treatment

  • Flotetuzumab

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02152956

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved